VEGF: Why Medicine Blocks It Rather Than Gives It

Vascular endothelial growth factor is the principal signal driving the formation of new blood vessels. It appears in this formulary because growing new vasculature sounds like an obvious regenerative goal. The clinical history says otherwise: attempts to administer VEGF therapeutically have largely failed, while drugs that block it have become some of the most successful in modern medicine.

This guide situates VEGF within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What VEGF does

VEGF is a family of secreted signaling proteins, of which VEGF-A is the principal player in blood vessel formation. It binds receptors on endothelial cells, driving their proliferation, migration and organization into new vessels, and it markedly increases vascular permeability — a property that turns out to matter clinically as much as the vessel growth itself.

Its expression is driven by hypoxia. Tissue that is not receiving enough oxygen stabilizes hypoxia-inducible factor, which upregulates VEGF, which recruits new vasculature. It is an elegant demand-driven system, and it operates in wound healing, in exercise adaptation, and in disease.

Why therapeutic angiogenesis did not work

The reasoning behind therapeutic angiogenesis was straightforward. In coronary artery disease and critical limb ischemia, tissue is ischemic because vasculature is inadequate. Supply VEGF, grow new vessels, restore perfusion.

Multiple clinical trials pursued this, using recombinant protein and gene transfer approaches. The results were largely disappointing, with trials generally failing to show durable clinical benefit despite encouraging preclinical work.

Several reasons emerged. Vessels formed under a single unopposed growth factor signal tend to be immature, leaky and poorly organized — mature functional vasculature requires a coordinated sequence involving multiple factors including PDGF for pericyte recruitment, not a single stimulus. The signal must also be sustained in the right place for the right duration, which a bolus of protein does not achieve. And VEGF's permeability effect produces edema and hypotension, dose-limiting problems in exactly the population being treated.

The general lesson matters beyond VEGF: a growth factor is a contextual instruction, not a building material. Supplying it out of its physiologic context does not reproduce the process it normally participates in.

Where blocking VEGF succeeded

The therapeutic wins in this pathway all came from inhibition.

In ophthalmology, anti-VEGF agents transformed the management of neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion. These conditions are driven by pathologic VEGF-mediated vessel growth and leakage, and blocking it preserves vision in patients who would previously have gone blind. It is one of the genuine treatment revolutions of recent decades.

In oncology, anti-VEGF therapy starves tumors of the vasculature they require to grow beyond a minimal size, and is used across several malignancies.

That oncologic application carries the direct corollary for anyone considering pro-angiogenic therapy: tumor growth depends on angiogenesis. Administering a systemic pro-angiogenic signal is a meaningful theoretical concern in any patient with known or occult malignancy, and it is a principal reason this approach is not pursued casually.

Status and practical relevance

There is no approved VEGF product for administration, and VEGF is not an established compounding substance. Material sold under this name outside a research setting is unregulated, and for a large signaling protein, whether it retains correct structure and activity is a genuine question.

Its relevance to practice is conceptual. Clinicians should understand that angiogenesis is a coordinated multi-factor process, that supplying one factor does not reconstruct it, and that pro-angiogenic intervention carries oncologic considerations. Related growth factors including PDGF and TGF-beta illustrate the same principle from different angles.